202 related articles for article (PubMed ID: 21304001)
21. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
Puzanov I; Milhem MM; Minor D; Hamid O; Li A; Chen L; Chastain M; Gorski KS; Anderson A; Chou J; Kaufman HL; Andtbacka RH
J Clin Oncol; 2016 Aug; 34(22):2619-26. PubMed ID: 27298410
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic viruses: a new class of immunotherapy drugs.
Kaufman HL; Kohlhapp FJ; Zloza A
Nat Rev Drug Discov; 2015 Sep; 14(9):642-62. PubMed ID: 26323545
[TBL] [Abstract][Full Text] [Related]
23. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Breitbach CJ; Moon A; Burke J; Hwang TH; Kirn DH
Methods Mol Biol; 2015; 1317():343-57. PubMed ID: 26072416
[TBL] [Abstract][Full Text] [Related]
24. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
25. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Markert JM; Razdan SN; Kuo HC; Cantor A; Knoll A; Karrasch M; Nabors LB; Markiewicz M; Agee BS; Coleman JM; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Weichselbaum RR; Fiveash JB; Gillespie GY
Mol Ther; 2014 May; 22(5):1048-55. PubMed ID: 24572293
[TBL] [Abstract][Full Text] [Related]
26. Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy.
Miles LA; Brennen WN; Rudin CM; Poirier JT
PLoS One; 2015; 10(6):e0129103. PubMed ID: 26069962
[TBL] [Abstract][Full Text] [Related]
27. Structural features of the Seneca Valley virus internal ribosome entry site (IRES) element: a picornavirus with a pestivirus-like IRES.
Willcocks MM; Locker N; Gomwalk Z; Royall E; Bakhshesh M; Belsham GJ; Idamakanti N; Burroughs KD; Reddy PS; Hallenbeck PL; Roberts LO
J Virol; 2011 May; 85(9):4452-61. PubMed ID: 21325406
[TBL] [Abstract][Full Text] [Related]
28. Senecavirus A.
Segalés J; Barcellos D; Alfieri A; Burrough E; Marthaler D
Vet Pathol; 2017 Jan; 54(1):11-21. PubMed ID: 27371541
[TBL] [Abstract][Full Text] [Related]
29. Development of an improved dual-promoter-based reverse genetics system for emerging Senecavirus A.
Zhang X; Lu J; Deng T; Zhao P; Peng Z; Chen L; Qian M; Guo Y; Qiao H; Song Y; Xia Y; Bian C; Wang Z
J Virol Methods; 2020 Dec; 286():113973. PubMed ID: 32941978
[TBL] [Abstract][Full Text] [Related]
30. Senecavirus A 3C Protease Mediates Host Cell Apoptosis Late in Infection.
Fernandes MHV; Maggioli MF; Otta J; Joshi LR; Lawson S; Diel DG
Front Immunol; 2019; 10():363. PubMed ID: 30918505
[TBL] [Abstract][Full Text] [Related]
31. Seneca Valley virus attachment and uncoating mediated by its receptor anthrax toxin receptor 1.
Cao L; Zhang R; Liu T; Sun Z; Hu M; Sun Y; Cheng L; Guo Y; Fu S; Hu J; Li X; Yu C; Wang H; Chen H; Li X; Fry EE; Stuart DI; Qian P; Lou Z; Rao Z
Proc Natl Acad Sci U S A; 2018 Dec; 115(51):13087-13092. PubMed ID: 30514821
[TBL] [Abstract][Full Text] [Related]
32. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
33. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results.
Packiam VT; Lamm DL; Barocas DA; Trainer A; Fand B; Davis RL; Clark W; Kroeger M; Dumbadze I; Chamie K; Kader AK; Curran D; Gutheil J; Kuan A; Yeung AW; Steinberg GD
Urol Oncol; 2018 Oct; 36(10):440-447. PubMed ID: 28755959
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.
Downs-Canner S; Guo ZS; Ravindranathan R; Breitbach CJ; O'Malley ME; Jones HL; Moon A; McCart JA; Shuai Y; Zeh HJ; Bartlett DL
Mol Ther; 2016 Aug; 24(8):1492-501. PubMed ID: 27203445
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Cripe TP; Ngo MC; Geller JI; Louis CU; Currier MA; Racadio JM; Towbin AJ; Rooney CM; Pelusio A; Moon A; Hwang TH; Burke JM; Bell JC; Kirn DH; Breitbach CJ
Mol Ther; 2015 Mar; 23(3):602-8. PubMed ID: 25531693
[TBL] [Abstract][Full Text] [Related]
39. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.
Breitbach CJ; Burke J; Jonker D; Stephenson J; Haas AR; Chow LQ; Nieva J; Hwang TH; Moon A; Patt R; Pelusio A; Le Boeuf F; Burns J; Evgin L; De Silva N; Cvancic S; Robertson T; Je JE; Lee YS; Parato K; Diallo JS; Fenster A; Daneshmand M; Bell JC; Kirn DH
Nature; 2011 Aug; 477(7362):99-102. PubMed ID: 21886163
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
